Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

While heartburn medication can be a lifesaver for those suffering from gastric reflux, several studies over the years have ...

The drug is not considered a cure, but results emerging from clinical trials point to the first major advancement in decades ...

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...